A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy

A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy in Previously Untreated CLL/SLL

Prospective, interventional, and practical clinical studies

Inclusion Criteria:

• Age between 18 and 70 years, with no gender restrictions;
• Patients with CLL/SLL who meet the iwCLL2018 diagnostic criteria;
• Indications for treatment
• ECOG performance score of 0-2;
• Patients are untreated or have not received standardized treatment
• Before the trial screening, the subject or their legal representative voluntarily signs a written informed consent form, indicating that they understand the purpose of the study and the necessary research steps, and are able to comply with the protocol and follow-up.

Exclusion Criteria:

• Has been diagnosed or treated for malignancies other than CLL (including active central nervous system lymphoma) within the past year;
• there is clinical evidence of Richter transformation;
• Participant cannot receive or plan to receive another treatment during study participation
• Other conditions that the investigator considers inappropriate for participation